About PharmaWire.org
News, analysis and commentary on the pharmaceutical and biotech industry.
PharmaWire.org tracks the deals, data and breakthroughs driving the future of pharma. We publish news on mergers and licensing, regulatory decisions, clinical trial results, earnings, drug pricing and health policy, alongside longer market guides on rare diseases. The archive holds 354 articles and 39 company profiles.
What we cover
- Latest news, organised into deals, clinical, regulatory, markets, legal, policy, business, public health.
- Rare disease market insights: in-depth guides to treatments, pricing and competition.
- Company profiles: key facts and answers to common questions about major drugmakers and biotechs.
How our data pages work
The FDA decision calendar is refreshed every day. Approvals of new drugs and biologics come from openFDA, the FDA’s public data service. Advisory committee meetings come from notices in the US Federal Register, and agency announcements come from the FDA press release feed. Company-disclosed PDUFA target dates and European CHMP opinions are added from company statements and regulator publications. Every entry links to its source.
The deal tracker records announced biopharma acquisitions, mergers, licensing deals and partnerships, with headline and upfront values where disclosed, and a link to the original announcement.
Citing PharmaWire.org
You are welcome to quote our reporting with attribution to PharmaWire.org and a link to the original article. Search engines and AI assistants may crawl and cite the site.
